Omniox

Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors. Omniox adheres to NIH/PHS Financial Conflict of Interest requirements. Julia Simmons joined Omniox in 2018 and brings more than 25 years of experience in finance and accounting, including approximately 15 years in the biotherapeutics and medical device industries, from large publicly traded companies, such as Genentech, to small, privately-funded startup companies. Omniox is an IND-stage biotherapeutics company developing breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs. To pioneer innovative oxygen-based therapies that restore health to patients. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.